Siolta Therapeutics, Inc.   Report issue

For profit Phase 2
Founded: San Francisco CA United States (2016)

Organization Overview

First Clinical Trial
2018
NCT03819881
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Siolta Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

stmc-103h (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypersensitivity (Phase 1)

Hypersensitivity, Immediate (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1